“a nonsignificant trend”

Similarly, there was a nonsignificant trend toward decreased colectomy rates in the early flexible sigmoidoscopy group (17% vs 28%, P = .23).

For OS, pure transformation showed only a nonsignificant trend toward worse survival compared with de novo DLBCL ( p = 0.23), and OS did not differ significantly among de novo DLBCL, concurrent trDLBCL, and pure transformation (log-rank p = 0.56; Figure S1 ).

Conversely, MR‐Egger analysis depicted a nonsignificant trend (OR = 0.6372; 95% CI: 0.3511–1.1565, p = .230), suggesting the need for cautious interpretation. 5.3.3.

Infected females had a significantly increased risk of mortality compared to uninfected females (HR = 1.62; 95% CI: 1.03–2.54, p = 0.035; Supplemental Table S18 ), while infected males had a nonsignificant trend toward reduced mortality (HR = 0.50; 95% CI: 0.16–1.55, p = 0.23; Supplemental Table S14 ). 3.2.3.

Antiviral therapy was given to 10 patients, mostly in the high CMV IgG group (9/10), with a nonsignificant trend toward higher incidence ( P = .23).

There was a nonsignificant trend for increased EMB complications with surveillance indication ( P = 0.230).

In this study, a nonsignificant trend (p = 0.23) towards decreased visual acuity had occurred [from right after the RPE tear (baseline) compared to the 2-year follow-up] independent of the number of anti-VEGF treatments.

Recently, the final results were reported, where the primary endpoint of DFS revealed that UFT was inferior to S-1 (HR 1.23, 1.07-1.43), and that there was a nonsignificant trend (HR 0.92, 0.8-1.07; p = 0.23) to improved DFS with sequential PTX→FP versus FP alone [ 45 ].

As for the RTs, the high-AQ group showed a nonsignificant trend to respond more slowly than the low-AQ group (M = 4113 ms and M = 3903 ms, respectively; F (1, 40) = 1.47; p = 0.232).

This analysis revealed a nonsignificant trend towards higher firing rate during the 2 s preceding a spindle event (one-way RM ANOVA, χ 2 = 2.88, P = 0.24).

16.2%; p = 0.025), while pleural injury demonstrated a nonsignificant trend toward reduction (0% vs. 8.1%; p = 0.240).

After a median follow-up of 4.7 years, losartan 150 mg/day significantly reduced hospital admissions for HF (HR 0.87; 95% CI: 0.76–0.98; P = 0.025) and showed a nonsignificant trend towards reduction in mortality (HR 0.94; 95% CI: 0.84–1.04; P = 0.24) as compared with losartan 50 mg/day.

A nonsignificant trend favoring UST in the clinical response rate (52% vs. 25%, p < 0.24) and the clinical remission rate (25% vs. 27%, p < 0.82) was observed, as expected, in the subgroup of anti-TNFα–experienced patients [ 22 ].

ITM dose (continuous) explained 13% of the between-study variance (R 2 = 13.3%), with a nonsignificant trend toward diminishing analgesic benefit at higher doses (β = −2.48 SMD per mg; 95% CI: −6.61 to +1.64; p = 0.24).

Interestingly, no significant differences in the prevalence of discordance due to abnormal resting Pd/Pa were found, although a nonsignificant trend toward decrement with age was noted (9.9% vs. 7.9%, p = 0.244).

Number of Sessions, Need for Mechanical Lithotripsy, and Procedure Duration Among the four studies [ 17 – 19 , 21 ] that reported the mean number of sessions needed for complete stone clearance, there was a nonsignificant trend toward fewer sessions needed among those who underwent ES + EPLBD versus ES (1.3 ± 0.3 versus 1.8 ± 0.7, P = 0.245).

This Class B profile was almost completely absent in patients with 2 copies of the MICB G406A variant allele, only 1 of 31 patients, and there was a nonsignificant trend toward reduced odds of having the Class B profile with increasing copies of the MICB G406A variant allele ( Figure 7D ; P = 0.248, P adj = 0.1).

A nonsignificant trend was retained in multivariable analysis (HR 1.32; 95% CI 0.83–2.10; P = 0.249).

During treatment, there was a nonsignificant trend for a lower am H‐SBP for active (129.6±8.9 mm Hg) versus sham (134.6±9.6 mm Hg; P =0.25; Figure [ B ]).

Female sex showed a nonsignificant trend toward an increased risk (OR: 1.47, 95% CI: 0.76–2.84, p = 0.250).

Finally, pooled datasets from two RCTs from the Leuven ICUs reported a nonsignificant trend of lowering the risk of critical illness-induced polyneuropathy in patients with diabetes (odds ratio, 0.62; P = 0.25) ( 4 ).

There was a nonsignificant trend toward longer mean duration of concomitant immunomodulator use in those without LOR at 2.39 years versus 1.08 years for those with LOR, p = 0.252.

There is a nonsignificant trend toward a higher PT (22.16 ± 7.05 vs 20.57 ± 8.36°; P = .253) and PI (53.07 ± 10.21 vs 52.60 ± 9.85°; P = .783) in the DLS group.

PEGSerp-1 treatment produced a nonsignificant trend toward reduced CD4 T cell count in the 5% acute DSS models (Fig. 6 D, p = 0.2556).

67.2 ± 7.7 g/L, p < 0.001), whereas serum ADA showed a nonsignificant trend toward higher values (28.2 ± 7.2 vs. 26.2 ± 8.6 U/L, p = 0.256).